X4 PHARMACEUTICALS, INC Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
X4 PHARMACEUTICALS, INC (XFOR) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $29.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-17
- X4 PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $29.28M, a 39.99% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $20.91M, a 32.28% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $30.88M.
- X4 PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2018 was $10.49M, a 35.77% increase from fiscal 2017.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $29.28M 10-K · filed 2026-03-17 |
| 2024-12-31 | $20.91M 10-K · filed 2026-03-17 |
| 2023-12-31 | $30.88M 10-K · filed 2026-03-17 |
| 2018-12-31 | $10.49M 10-K · filed 2019-03-11 |
| 2017-12-31 | $7.73M 10-K · filed 2019-03-11 |
| 2016-12-31 | $7.64M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |